Member Info for OAPK20

Neil to be fair you say the same thing after an email.

Same people same employer Trans

No mention of board putting hands in their pockets for this ?

No progress.

Same old same old.

But this bit “ Progress the Company's proprietary CIZ1B biomarker blood test through to UKCA, CE marking and/or FDA 510(k) clearance and;”

Something progressing or not.

Too busy pumping OCTP.

Thoughts

“ Novartis is buying a gene therapy candidate from the cash-constrained Avrobio, striking an unusual deal that will see the Big Pharma pay $87.5 million without committing milestones or royalties to land the clinical-phase asset. The news comes months after Novartis was reported to be lining up a takeover of the biotech.

The deal covers AVR-RD-04, an investigational hematopoietic stem cell gene therapy program for the treatment of the rare genetic condition cystinosis. In February, data from a phase 1/2 trial sponsored by the University of California, San Diego revealed the first five patients had stopped taking oral cysteamine, the drug used to tackle the buildup of cystine crystals that drives cystinosis, after receiving the therapy.

Based on the data, Avrobio was gearing up to start a registration-enabling phase 1/2 study in the second half of the year. However, the biotech has changed its plans, choosing to sell the candidate to Novartis for an all-in price of $87.5 million. However successful the therapy is, that sum is all Avrobio will receive.”

Whispers? Rumours? Genuine? Complete fabrication? Pump n dump or something else…..

“ significant progress has been made in characterising and optimizing the company's antibodies for use and scale up into the configuration required for further clinical trials ahead of the launch of commercial early stage lung cancer assays. ”

CIZ and the board need to get a shift on or a less accurate test is going to beat them to it.

NHS trial results of the liquid biopsy, published at the world’s largest cancer conference in the US, suggest the Galleri blood test has the potential to spot and rule out cancer in people with symptoms.

The test detects tiny fragments of tumour DNA in the bloodstream. It alerts doctors as to whether a cancer signal has been detected, and predicts where in the body that signal might have originated.

Experts welcomed the findings from the trial but also said more research would be needed before the test, made by the California company Grail, could be rolled out in healthcare systems.

The Symplify study, led by the University of Oxford, involved 5,461 people in England and Wales who were referred to hospital by their GP with suspected cancer. Its results are being presented at the American Society of Clinical Oncology’s annual meeting in Chicago.

The test correctly revealed two-thirds of cancers among those in the study. In 85% of those positive cases, it was also able to pinpoint the original site of cancer. It was more accurate in older patients, and those with more advanced cancers, according to the trial results.

The last company RNS Number : 4551Z wasn’t a pump ?

Not Kissei ? Not Both. Or tooooo rampy?

Came across tetchy there Neilin. Think people are rightly disappointed this was pumped to 4.8 and now sits at 2.25. There were positive tweets but no concrete RNS update. Not everyone bought in lower. There maybe an opportunity if there is a drawdown. Wait and see what happens if there is a drawdown it'll be full on pump mode again to flip.

This needs a positive update regarding progress

27,777,778 shares.

Not my experience. NT to sell can buy plenty. Waiting.

- A further Facility of GBP500,000 is available to the Company, subject to Admission, to provide further funds, if required, repayable in shares at a fixed price of 1.8p per share

Pumping and dumping. This was pumped hard. 8p bottom support if that goes …..

Feel for those who held from the pump and spike. Clavara trial update better be good to offset any bad news in the results. How much is left from the £10mill placing ?

No TR1 RNS from large holders reducing is an encouraging silence so far.

Joe once a Mega RNS lands it’ll be a Mega Pint you’ll need

NFTs

Posted in: NFX

Posts: 281

Price: 0.325

No Opinion

RE: RNS NXP002 Update - excellent27 Mar 2023 08:21

Yes

I have to say this reads very well for showing the value that NXP002 holds. IPF is particularly difficult area with desperate need for fast to market affordable therapies and NXP002 is exactly that. Perhaps Kissei maybe interested again ;)

MURF authorised to issue 100,000,000 Class A common shares

Less issued gives - Class A - 83,833,272 potentially to issue.

On completion of Conduit merger

A private placement transaction shall be conducted by the Company contemporaneously with the Business Combination (the “PIPE Financing”), pursuant to which the Company has entered into subscription agreements providing for aggregate investments in the Company’s securities of $27,000,000.

PIPE Financing - Class A common stock - 2,700,000 shares @ $10.

Add to the balance in the Trust Account which was approximately $24 million.

Gives $51,000,000 and complies with $50 million minimum MVLS requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A)

Looks like initial PIPE Financiers have taken $0.33 cent per share profit and now have cash available for next round before Conduit merger.

Conduit get - Class A common stock - 65,000,000 @ $10

So MURF have plenty headroom to issue Class A common stock - 67,500,000 shares.

Pursuant to the BCA, at the closing, the Company shall issue and deliver to the shareholders of Conduit an aggregate number of shares of the Company’s common stock with an aggregate value equal to $650,000,000, with each share valued at $10.00 per share. A private placement transaction shall be conducted by the Company contemporaneously with the Business Combination (the “PIPE Financing”), pursuant to which the Company has entered into subscription agreements providing for aggregate investments in the Company’s securities of $27,000,000.

Class A Common Stock — The Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. As of March 31, 2023 and December 31, 2022, there were 754,000 and zero, respectively, shares of Class A common stock issued and outstanding (excluding the 2,187,728 shares and 13,225,000 shares subject to possible redemption as of March 31, 2023 and December 31, 2022, respectively). During the three months ended March 31, 2023, a total of 11,037,272, shares of Class A common stock were redeemed for $114,068,280 or approximately $10.33 per share.

Bufflehead - " Know what to say & when "

Last RNS appeared after it was posted on BB's. Why and for whose benefit. Not PI's that's for sure.